Vascular Biogenics Ltd. (VBLT) SEC Filing 6-K Foreign Issuer Report for the period ending Thursday, March 31, 2022

Vascular Biogenics Ltd.

CIK: 1603207 Ticker: VBLT

View differences made from one to another to evaluate Vascular Biogenics Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vascular Biogenics Ltd..


Assess how Vascular Biogenics Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Vascular Biogenics Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Vascular Biogenics Ltd. provided additional information to their SEC Filing as exhibits

Ticker: VBLT
CIK: 1603207
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001493152-22-014080
Submitted to the SEC: Tue May 17 2022 7:00:49 AM EST
Accepted by the SEC: Tue May 17 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: